GRTS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 112268 min ago

@ $2.18

Išleistas: 14 vas. 2024 @ 21:06

Grąža: -61.24%

Ankstesnis signalas: vas. 13 - 22:42

Ankstesnis signalas: Pardavimas

Grąža: 3.82 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 21:14):

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases...

Stats
Šios dienos apimtis	920 692
Vidutinė apimtis	2.78M
Rinkos kapitalizacija	89.70M
EPS	$0 ( 2024-03-14 )
Kita pelno data	( $-0.300 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.700
ATR14	$0.00400 (0.47%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-26	Webster Stephen W	Buy	103 600	Stock Option (Right to Buy)
2024-04-26	Webster Stephen W	Sell	0	Common Stock
2024-02-01	Hawryluk Matthew	Buy	35 000	Common Stock
2024-02-01	Hawryluk Matthew	Buy	180 000	Stock Option (Right to Buy)
2024-02-01	Jones Erin	Buy	40 000	Common Stock

INSIDER POWER
100.00
Last 97 transactions
Buy: 6 032 442 \| Sell: 138 571

Tūris Koreliacija

Ilgas: 0.00 (neutral)

Trumpas: 0.94 (very strong)

Signal:(55.897) Expect same movement, but be aware

Gritstone Oncology Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Gritstone Oncology Inc Koreliacija - Valiuta/Žaliavos

-0.58
( weak negative )

0.33
( neutral )

0.00
( neutral )

-0.47
( neutral )

Gritstone Oncology Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$1.33M
Bruto pelnas:	$-6.26M (-470.32 %)
EPS:	$-1.200

FY	2023
Pajamos:	$1.33M
Bruto pelnas:	$-6.26M (-470.32 %)
EPS:	$-1.200

FY	2022
Pajamos:	$9.27M
Bruto pelnas:	$-6.42M (-69.28 %)
EPS:	$-1.240

FY	2021
Pajamos:	$48.21M
Bruto pelnas:	$48.21M (100.00 %)
EPS:	$-0.965

Financial Reports:

No articles found.

Gritstone Oncology Inc

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.